With its FY15 results, Probiodrug provided an update on the lead Phase IIa SAPHIR trial, which is well underway. R&D expenses were up year-on-year reflecting increased activities related to the study. The six-month delay was mainly a result of enrolment difficulties, which is not uncommon in Alzheimer’s disease (AD) studies due to increasing competition for the same early patient population. Importantly, measures taken by the company addressed this issue well, in our view. The final
31 Mar 2016
Tolerable SAPHIR delay, full data early 2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Tolerable SAPHIR delay, full data early 2017
Vivoryon Therapeutics N.V. (VVY:AMS) | 0 0 0.0%
- Published:
31 Mar 2016 -
Author:
Jonas Peciulis -
Pages:
6
With its FY15 results, Probiodrug provided an update on the lead Phase IIa SAPHIR trial, which is well underway. R&D expenses were up year-on-year reflecting increased activities related to the study. The six-month delay was mainly a result of enrolment difficulties, which is not uncommon in Alzheimer’s disease (AD) studies due to increasing competition for the same early patient population. Importantly, measures taken by the company addressed this issue well, in our view. The final